Prelude Therapeutics Incorporated
- PRLD
- NASDAQ
- Biotechnology
- Precision Oncology
- Targeted Cancer Therapies
$3.39
Today +3.99%Quote Oct 19, 2026, 08:00 PM UTC
−30.39%over the last month
Max drawdown −33.7%From 1-month high −30.4%3 months −16.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Prelude Therapeutics
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
79
Founded
2016
Market value
$270.5M
Quote Oct 19
Analyst target
$8.00
+136.0% from here
Floor
$3.00
11.6% below price
Resistance
$3.46
2.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PRLDPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free